Format

Send to

Choose Destination
J Am Coll Cardiol. 2013 Jul 9;62(2):96-102. doi: 10.1016/j.jacc.2013.02.089. Epub 2013 May 9.

Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy.

Author information

1
Quebec Heart & Lung Institute, Quebec City, Quebec, Canada.
2
Quebec Heart & Lung Institute, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.
3
Montreal Heart Institute, Montreal, Quebec, Canada.
4
Vancouver General Hospital, Vancouver, British Columbia, Canada.
5
St. Paul's Hospital, Vancouver, British Columbia, Canada.
6
Toronto General Hospital, Toronto, Ontario, Canada.
7
Royal Columbian Hospital, Vancouver, British Columbia, Canada.
8
Ottawa Heart Institute, Ottawa, Ontario, Canada.
9
Montreal Heart Institute, Montreal, Quebec, Canada. Electronic address: reda.ibrahim@icm-mhi.org.

Abstract

OBJECTIVES:

The aim of this study was to evaluate the results associated with left atrial appendage closure (LAAC) with the AMPLATZER Cardiac Plug (ACP) (St. Jude Medical, Minneapolis, Minnesota) in patients with nonvalvular atrial fibrillation and absolute contraindications to anticoagulation therapy.

BACKGROUND:

Few data exist on the late outcomes after LAAC in patients with absolute contraindications to warfarin.

METHODS:

A total of 52 patients with nonvalvular atrial fibrillation underwent LAAC with the ACP device in 7 Canadian centers. Most patients received short-term (1 to 3 months) dual-antiplatelet therapy after the procedure and single-antiplatelet therapy thereafter. A transesophageal echocardiography was performed in 74% of patients at the 6-month follow-up. No patient was lost to follow-up (≥ 12 months in all patients).

RESULTS:

The mean age and median (interquartile range) CHADS2 score were 74 ± 8 years and 3 (2 to 4), respectively. The procedure was successful in 98.1% of the patients, and the main complications were device embolization (1.9%) and pericardial effusion (1.9%), with no cases of periprocedural stroke. At a mean follow-up of 20 ± 5 months, the rates of death, stroke, systemic embolism, pericardial effusion, and major bleeding were 5.8%, 1.9%, 0%, 1.9%, and 1.9%, respectively. The presence of mild peridevice leak was observed in 16.2% of patients at the 6-month follow-up as evaluated by transesophageal echocardiography. There were no cases of device thrombosis.

CONCLUSIONS:

In patients with nonvalvular atrial fibrillation at high risk of cardioembolic events and absolute contraindications to anticoagulation, LAAC using the ACP device followed by dual-/single-antiplatelet therapy was associated with a low rate of embolic and bleeding events after a mean follow-up of 20 months. No cases of severe residual leak or device thrombosis were observed at the 6-month follow-up.

PMID:
23665098
DOI:
10.1016/j.jacc.2013.02.089
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center